Open AccessEfficacy of rigosertib, a small molecular RAS signaling disrupter for the treatment of <i>KRAS</i>-mutant colorectal cancer
Author(s) -
Xinyi Zhou,
Qian Xiao,
Dongliang Fu,
Haochen Zhang,
Yang Tang,
Jinjie He,
Yeting Hu,
Xianglong Kong,
Fei Teng,
Xiangrui Liu,
Ying Yuan,
KeFeng Ding
Publication year - 2021
Publication title -
cancer biology and medicine
Language(s) - English
Resource type - Journals
ISSN - 2095-3941
DOI - 10.20892/j.issn.2095-3941.2020.0532
Subject(s) - kras , cancer research , apoptosis , protein kinase b , colorectal cancer , pi3k/akt/mtor pathway , cell cycle , mapk/erk pathway , cell growth , cancer , chemistry , biology , signal transduction , medicine , microbiology and biotechnology , biochemistry
Mutant KRAS, the principal isoform of RAS, plays a pivotal role in the oncogenesis of colorectal cancer by constitutively activating the RAF/MEK/ERK and PI3K/AKT pathways. Effective targeted therapies are urgently needed. We investigated whether rigosertib, a benzyl styryl sulfone RAS signaling disruptor, could selectively kill KRAS -mutant colorectal cancer cells.